Ayana Pharma’s Generic, Cancer-killing Drug Got FDA Approval
Ayana Pharma’s Generic, Cancer-killing Drug Approved for Marketing by FDA The American Food and Drug Administration (FDA) has approved a groundbreaking, complex, generic drug indicated
Image Navigation is ushering in a New Era of Navigated and Robotic Dentistry!
Image Navigation is raising next round of funding for $8.5 million towards launch in US and European markets in 2022. Image Navigation, Ltd. Is preparing
Healables: A wearable that soothes and heals at home
Abigail Leichman from Israel21C visited Healables.ios in Jerusalem and met with Moshe Lebowitz, CEO of Healables.io (on the left, in the picture above, speaking to
Oramed Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
Oramed Pharmaceuticals Inc., a Jerusalem-based clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, has enrolled over 50% of patients planned for
KAHR to Utilize $46.5 Million Financing to Advance Its Multifunctional Immunotherapeutic Pipeline
KAHR, a Jerusalem-based cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, has closed an investment round raising $46.5 million. The financing was led by aMoon
JLM’s illumigyn Closes Deal in UAE for its “Gynecology Endoscope” Cloud Platform
illumigyn, an Israeli company that provides a cloud platform service called GynescopeTM Systems, has signed a Memorandum of Understanding with Dubai-based Company DHI 2048 to
Genetika+, Pioneer in Personalized Medicine for Psychiatry, Raises $10 Million
Jerusalem-based Genetika+, bringing the first personalized medicine platform for optimizing psychiatric and neurologic patient treatment, has closed a $10 million oversubscribed Series A funding round
Mirror Biologics has Initial Clearance for Phase II/III Clinical Trial in Advanced Liver Cancer
Mirror Biologics, Inc. announced the clearance of the “ALIVE” Phase II/III randomized, controlled clinical trial for subjects with advanced, treatment-naïve, Hepatocellular Carcinoma (HCC) by the
Jerusalem-based NewStem Ltd. Selected for the Global Illumina Accelerator
NewStem, along with six other genomic companies, was selected by Illumina for its global Illumina Accelerator. NewStem Ltd main investor, NovelStem International Corp. m
